Asthma Inhalers for Children: Steroids, Spacers and Step-Up Treatment
TL;DR
- Most children with persistent asthma need a daily inhaled corticosteroid (ICS) such as fluticasone or budesonide — these are the cornerstone of treatment from GINA Step 2 onward.
- A valved holding chamber (spacer) is essential for all children using a pressurised metered-dose inhaler (pMDI); it dramatically improves drug delivery and reduces side effects.
- SABA-only treatment (salbutamol/albuterol as needed) is no longer recommended as first-line — even in mild asthma, ICS should accompany reliever use.
- Montelukast carries an FDA boxed warning for neuropsychiatric effects and should be reserved for children who cannot use or tolerate ICS.
- Step-up decisions — adding long-acting beta-agonists (LABA), increasing ICS dose, or considering biologics — should follow GINA/NICE stepwise protocols with regular reassessment.
Understanding Childhood Asthma and Why Inhalers Matter
Asthma is the most common chronic disease of childhood worldwide. The Global Initiative for Asthma (GINA) estimates that approximately 5–10% of children are affected globally, with prevalence varying substantially by region and socioeconomic factors. In the United States, the Centers for Disease Control and Prevention (CDC) reports a prevalence of roughly 7% among children under 18, with disproportionately higher rates in Black and Puerto Rican children.
The disease is characterised by chronic airway inflammation, bronchial hyper-responsiveness, and variable airflow obstruction. In children, this manifests as recurrent episodes of wheeze, cough (particularly nocturnal), chest tightness, and breathlessness. A child asthma inhaler — whether delivering a corticosteroid, a bronchodilator, or both — remains the primary drug-delivery mechanism because it targets the airways directly, minimises systemic exposure, and works faster than oral alternatives.
The pathophysiology in paediatric patients overlaps with, but is not identical to, adult disease. Young children (under 5) frequently exhibit virus-triggered episodic wheeze that may or may not evolve into persistent asthma. Older children more commonly display the allergic (atopic) phenotype with eosinophilic airway inflammation highly responsive to ICS. This distinction matters clinically: a 2-year-old wheezing with every cold requires a different management conversation than an 8-year-old with exercise-triggered symptoms and a positive skin-prick test.
GINA Stepwise Treatment for Children: An Overview
Both GINA (2023 update) and NICE (NG80, updated 2024) recommend a stepwise approach that escalates therapy based on symptom control and exacerbation risk. GINA separates recommendations into two age tracks — children 6–11 years and children 5 years and under — because evidence, device capability, and safety data differ between these groups.
Children 6–11 Years (GINA Steps 1–5)
| Step | Preferred Controller | Preferred Reliever | Alternative Controller |
|---|---|---|---|
| 1 | Low-dose ICS taken whenever SABA used | As-needed SABA | — |
| 2 | Daily low-dose ICS | As-needed SABA | LTRA (montelukast) or low-dose ICS taken whenever SABA used |
| 3 | Low-dose ICS + LABA, or medium-dose ICS | As-needed SABA | Low-dose ICS + LTRA |
| 4 | Medium-dose ICS + LABA (specialist referral) | As-needed SABA | Add-on tiotropium or high-dose ICS + LABA |
| 5 | Refer for phenotypic assessment; consider biologics (omalizumab, mepolizumab from age 6+) | As-needed SABA | Add-on low-dose oral corticosteroids (last resort) |
Source: GINA 2023, Box 6-7. LTRA = leukotriene receptor antagonist.
Children ≤5 Years
For this age group, GINA recommends daily low-dose ICS at Step 2 (nebulised budesonide or fluticasone via pMDI + spacer with facemask) and stepping up to double-dose ICS or adding montelukast at Step 3. LABA use is not well-established below age 4–5. The reliever at all steps remains as-needed inhaled SABA.
Key point on ICS + formoterol maintenance and reliever therapy (MART): GINA endorses MART with low-dose budesonide–formoterol for adults and adolescents ≥12 years. MART is not currently recommended for children under 12 in GINA 2023 or NICE NG80 due to insufficient safety and efficacy data in this age group. Some specialist centres use it off-label in children 6–11 with frequent exacerbations, but this should only occur under specialist supervision.
Inhaled Corticosteroids: Fluticasone, Budesonide and Beyond
ICS are the most effective controller therapy for childhood asthma across all major guidelines. They reduce airway inflammation, decrease exacerbation frequency by 30–50%, improve lung function, and reduce asthma mortality.
Comparing ICS Options for Children
| ICS (INN) | Common Brands | Delivery Devices | Low Dose (6–11 yr) | Medium Dose (6–11 yr) | Notes |
|---|---|---|---|---|---|
| fluticasone propionate | Flixotide, Flovent | pMDI, DPI (Accuhaler/Diskus) | 50–100 µg/day | 100–200 µg/day | Widely studied in children; twice-daily dosing |
| budesonide | Pulmicort | DPI (Turbuhaler), nebuliser suspension | 100–200 µg/day | 200–400 µg/day | Gold standard in preschoolers via nebuliser; once-daily option at low dose |
| beclometasone dipropionate | Qvar, Clenil | pMDI | 50–100 µg/day (HFA) | 100–200 µg/day (HFA) | Older agent; extra-fine formulation (Qvar) has higher lung deposition |
| ciclesonide | Alvesco | pMDI | 80 µg/day | 160 µg/day | Prodrug activated in the lung; minimal oropharyngeal effects; once-daily |
| mometasone furoate | Asmanex | DPI (Twisthaler) | 100 µg/day | 200 µg/day | Approved from age 4+ in some markets |
Dose ranges from GINA 2023 and BTS/SIGN 2019. Low-dose equivalences are approximate and depend on device and formulation.
Fluticasone propionate is one of the most prescribed child asthma inhaler medications worldwide, supported by extensive paediatric trial data. The PEAK trial (Guilbert et al., NEJM 2006) demonstrated that 2 years of fluticasone in preschoolers reduced symptom-free days during treatment but did not modify the natural history of asthma once stopped — an important finding for parent counselling.
Budesonide has the largest safety database in paediatric asthma, partly due to the long-running START trial and extensive Scandinavian registry data. Its availability as a nebuliser suspension makes it the go-to ICS for children under 4 who cannot coordinate a pMDI + spacer with mask effectively.
Growth Effects — What to Tell Parents
The most common concern parents raise about ICS is growth suppression. The evidence is nuanced:
- Short-term (first 1–2 years): A modest reduction in growth velocity of approximately 0.5–1.0 cm/year is consistently observed with low-to-medium-dose ICS, most pronounced in prepubertal children (Kelly et al., Cochrane Database Syst Rev 2012).
- Long-term adult height: The CAMP (Childhood Asthma Management Program) follow-up study found that budesonide-treated children reached a mean adult height approximately 1.2 cm less than placebo (Kelly et al., NEJM 2012). This effect was dose-dependent and non-progressive.
- Clinical perspective: Uncontrolled asthma itself impairs growth, and the small deficit from low-dose ICS is generally considered an acceptable trade-off for preventing exacerbations, hospitalisations, and oral corticosteroid courses — which carry far greater systemic effects.
NICE and AAP both recommend using the lowest effective ICS dose, reviewing control every 3 months, and stepping down when asthma is well-controlled for at least 3 months.
Spacer Technique: The Most Underused Skill in Paediatric Asthma
A spacer (valved holding chamber, VHC) is not optional — it is essential equipment for any child using a pMDI. Without a spacer, only 10–20% of the emitted dose reaches the lower airways. With a properly used spacer, delivery improves to 20–40%, and oropharyngeal deposition (responsible for oral candidiasis and dysphonia) drops substantially.
Step-by-Step Spacer Technique
- Assemble the spacer and check the valve moves freely. Attach the facemask for children under 4–5 years; use a mouthpiece for older children.
- Shake the pMDI canister vigorously for 5 seconds.
- Insert the pMDI into the back port of the spacer.
- Seal the mask firmly over the child's nose and mouth (no gaps), or have the child close lips around the mouthpiece.
- Actuate one puff into the spacer.
- Breathe — the child takes 5–6 tidal breaths (or a slow deep inhalation followed by 10-second breath-hold if old enough). Listen for the valve clicking.
- Wait 30 seconds, then repeat for the second puff if prescribed.
- Rinse the mouth with water after ICS use and spit (do not swallow).
Common Spacer Errors
| Error | Consequence | Fix |
|---|---|---|
| Actuating multiple puffs at once | Drug precipitates onto spacer walls; only a fraction inhaled | One puff at a time, breathe, then next puff |
| Delayed inhalation (>5 seconds) | Aerosol settles in chamber | Breathe immediately after actuation |
| Poor mask seal | Drug escapes around mask edges; deposits on face/eyes | Firm seal; check for crying (reduces delivery) |
| Static charge on spacer | Attracts particles to walls | Wash spacer with dilute detergent, drip-dry (do not towel-dry) |
| Not replacing spacer | Worn valves and cracked plastic reduce function | Replace every 6–12 months or per manufacturer |
NICE NG80 and BTS/SIGN 2019 both recommend that pMDI + spacer is at least as effective as a nebuliser for acute and maintenance therapy in children and is the preferred delivery method. Nebulisers should be reserved for severe acute exacerbations in emergency settings or for children unable to use a spacer at all.
SABA Overuse: A Red Flag, Not a Safety Net
Short-acting beta-agonists — salbutamol (Ventolin) or albuterol — provide rapid bronchodilation and remain essential rescue medications. However, SABA overuse is a well-established marker for poor asthma control and increased mortality risk.
GINA 2023 highlights the following:
- Using ≥3 SABA canisters per year is associated with increased exacerbation risk.
- Using ≥12 SABA canisters per year is associated with increased mortality risk.
- SABA use without concurrent ICS treats symptoms but does nothing for underlying inflammation — creating a dangerous cycle of worsening disease masked by symptom relief.
For clinicians and parents alike: if a child is using their blue inhaler more than twice a week (outside of exercise pre-treatment), their asthma is not controlled, and controller therapy needs to be started or stepped up. This threshold applies to children at GINA Step 1 and above.
The AAP and GINA both now recommend that even at Step 1 (mild intermittent symptoms), children 6–11 should take low-dose ICS each time SABA is used, rather than using SABA alone.
Montelukast: Role, Limitations, and the FDA Boxed Warning
Montelukast (Singulair) is a leukotriene receptor antagonist (LTRA) approved for asthma in children as young as 12 months (granules), 2 years (chewable tablets), and 6 years and older (film-coated tablets). It works by blocking cysteinyl leukotriene receptors (CysLT1), reducing bronchoconstriction, mucus secretion, and eosinophilic inflammation.
Where Montelukast Fits
- GINA Step 2 alternative when ICS is refused, not tolerated, or causes unacceptable side effects.
- Add-on to low-dose ICS at Step 3 as a second-line alternative to adding a LABA.
- Exercise-induced bronchoconstriction — some evidence for benefit when taken daily.
- Concurrent allergic rhinitis — montelukast treats both conditions, which can simplify regimens.
The FDA Boxed Warning (2020)
In March 2020, the FDA strengthened the montelukast warning to a boxed warning — the agency's most prominent safety alert — based on post-marketing reports of serious neuropsychiatric events including:
- Agitation, aggression, hostility
- Depression, suicidal ideation, suicidal behaviour
- Sleep disturbances (insomnia, vivid dreams, sleepwalking)
- Anxiousness, hallucinations
- Attention and memory impairment
The FDA concluded that the benefits of montelukast do not outweigh the risks for patients with mild symptoms, particularly when alternative therapies (ICS) are available. The AAP and GINA both position montelukast as a second-line agent, not a first-choice controller.
Practical guidance for parents: If a child is started on montelukast, caregivers should be counselled to watch closely for mood changes, sleep disturbances, or behavioural shifts — especially in the first weeks. If neuropsychiatric symptoms emerge, the drug should be stopped and the prescriber contacted promptly. Many children tolerate montelukast without issues, but informed consent and active monitoring are essential.
Side Effects, Monitoring, and Long-Term Safety
ICS Side Effects in Children
| Side Effect | Frequency | Prevention / Management |
|---|---|---|
| Oral candidiasis (thrush) | Common with higher doses | Rinse and spit after each ICS dose; use spacer |
| Dysphonia (hoarse voice) | Occasional | Spacer use; dose reduction if possible |
| Growth velocity reduction | Common (0.5–1 cm/year in first 1–2 years) | Use lowest effective dose; monitor height on growth chart |
| Adrenal suppression | Rare at low–medium doses; risk increases at high doses | Avoid prolonged high-dose ICS; consider morning dosing; sick-day rules for adrenal crisis |
| Reduced bone mineral density | Very rare in children at standard doses | Ensure adequate calcium and vitamin D intake |
| Skin thinning / easy bruising | Very rare in paediatric age group | More relevant to adults on long-term high-dose therapy |
Monitoring Schedule
- Every 3 months (or at minimum every 6 months): assess symptom control (ACT or c-ACT score), inhaler technique, adherence, and trigger avoidance.
- At every visit: plot height on age-appropriate growth chart.
- Annually: review step-up/step-down decisions; assess whether the child still needs the current treatment level.
- Spirometry (children ≥6): at diagnosis, after 3–6 months of treatment, and periodically thereafter. NICE recommends spirometry with reversibility testing as part of the diagnostic workup in children 5–16.
Special Populations and Considerations
Preschool Children (Under 5 Years)
Diagnosing asthma in preschoolers is inherently uncertain — objective lung function testing is generally not feasible, and episodic viral-induced wheeze is common in this age group. GINA recommends a therapeutic trial of low-dose ICS for 2–3 months in children with a pattern suggestive of asthma (recurrent wheeze, atopic history, symptom persistence between colds). If the child responds, continue and reassess; if not, reconsider the diagnosis.
Device selection: pMDI + spacer with facemask is preferred. Budesonide nebuliser suspension (0.25–0.5 mg twice daily as low dose) is an alternative when spacer use is not possible.
Exercise-Induced Bronchoconstriction (EIB)
Affects up to 90% of children with uncontrolled asthma. First-line management is optimising controller therapy (ICS). For breakthrough EIB, a SABA 15–20 minutes before exercise is standard. Daily montelukast or pre-exercise montelukast may provide additional benefit but should not replace adequate ICS therapy.
Asthma in Adolescents (12–17 Years)
This population deserves specific attention because:
- Adherence declines sharply during adolescence.
- MART (budesonide–formoterol as maintenance and reliever) becomes an option from age 12, per GINA.
- Smoking and vaping uptake can dramatically worsen asthma control.
- Transition planning to adult services should begin around age 14–16.
Obesity and Asthma
Childhood obesity is an independent risk factor for asthma and is associated with poorer treatment response to ICS. Weight management should be addressed as part of the asthma action plan. Some evidence suggests that obese children with asthma may have a less eosinophilic, more neutrophilic phenotype.
Red Flags — When to Seek Urgent Medical Care
Take your child to the emergency department or call emergency services if:
- The reliever inhaler is not helping within 10–15 minutes, or the effect wears off rapidly.
- The child is too breathless to speak, eat, or drink.
- Breathing rate is markedly increased for age (>40 breaths/min in a child 1–5 years; >30 breaths/min in a child 6–11 years).
- There are visible intercostal, subcostal, or sternal retractions (skin pulling in around ribs).
- The child appears drowsy, confused, or exhausted from the work of breathing.
- Lips or fingernails appear blue or grey (cyanosis).
- Oxygen saturation <92% on a home pulse oximeter.
Contact the prescriber within 24–48 hours if:
- The child is using SABA more than twice per week.
- Nocturnal symptoms are waking the child more than once a week.
- Asthma is limiting normal activity or school attendance.
- A course of oral corticosteroids has been needed.
Frequently Asked Questions
1. Can my child become "addicted" to their steroid inhaler?
No. Inhaled corticosteroids are not addictive. They reduce airway inflammation with minimal systemic absorption at low-to-medium doses. Stopping ICS suddenly after prolonged high-dose use may cause a flare because the underlying inflammation returns — this is disease recurrence, not dependence. Always step down under medical guidance.
2. Is it safe to use a steroid inhaler every day for years?
Yes, for the vast majority of children. Large long-term studies (including the CAMP trial over 4+ years) confirm that daily low-dose ICS is safe and effective. The small potential effect on adult height (~1 cm) is generally outweighed by the benefits of controlled asthma, fewer hospitalisations, and avoidance of repeated oral corticosteroid courses.
3. My child's asthma seems well-controlled — can we stop the inhaler?
Possibly, but do not stop abruptly. GINA and NICE recommend maintaining good control for at least 3 months before considering step-down. Dose reduction should be gradual (typically halving the ICS dose), with reassessment after another 3 months. Some children outgrow their asthma, but many will need ongoing treatment.
4. What is the difference between a brown inhaler and a blue inhaler?
The brown (or orange/red) inhaler typically contains an ICS (preventer) — used daily to reduce inflammation. The blue inhaler contains a SABA like salbutamol (reliever) — used for acute symptom relief. A common and dangerous mistake is relying only on the blue inhaler while neglecting the preventer.
5. Should my child use a spacer even if they can use the inhaler without one?
Yes. A spacer improves lung deposition even with excellent technique, reduces oropharyngeal side effects, and eliminates the need for precise hand-breath coordination. NICE and BTS/SIGN recommend spacer use for all children using a pMDI, regardless of age or skill level.
6. My child was prescribed montelukast — should I be worried about side effects?
The FDA boxed warning is a serious alert, but it does not mean every child will experience neuropsychiatric effects. Discuss with your prescriber why montelukast was chosen over ICS. If there is a valid reason (ICS intolerance, concurrent allergic rhinitis, strong family preference against inhaled steroids), proceed with informed consent and monitor the child's behaviour and mood closely for the first several weeks.
7. At what age can a child switch from a spacer to a dry powder inhaler (DPI)?
Most children can begin to use a DPI effectively from around age 6–8, provided they can generate a sufficient inspiratory flow rate (typically ≥30 L/min for most devices). This should be assessed in clinic. Some children prefer DPIs because they are portable and do not require a spacer. However, during acute exacerbations, pMDI + spacer remains more reliable because inspiratory flow drops when airways are obstructed.
8. Is nebuliser treatment better than an inhaler with spacer?
For routine maintenance and most acute episodes — no. Multiple Cochrane reviews confirm that pMDI + spacer is at least as effective as nebuliser delivery for bronchodilators and corticosteroids in children, with fewer systemic side effects and faster administration. Nebulisers are reserved for severe acute presentations or children who absolutely cannot use a spacer.
References
-
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023 Update. Available at: ginasthma.org.
-
National Institute for Health and Care Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline NG80, updated 2024.
-
British Thoracic Society / Scottish Intercollegiate Guidelines Network (BTS/SIGN). British guideline on the management of asthma. SIGN 158. 2019.
-
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–1997. PMID: 16687711.
-
Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904–912. PMID: 22938716.
-
Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol. 2003;112(3):469–478. PMID: 13679803.
-
Castro-Rodriguez JA, Rodrigo GJ. Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr. 2004;145(2):172–177. PMID: 15289762.
-
Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;(9):CD000052. PMID: 24037768.
-
U.S. Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair). FDA Drug Safety Communication, March 2020.
-
The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063. PMID: 11027739.
-
Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database Syst Rev. 2014;(7):CD009471. PMID: 25030198.
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in hospital and ambulatory care pharmacy. He holds a Doctor of Pharmacy degree and has practiced across paediatric, internal medicine, and critical care settings. Dr. Ozarchuk writes evidence-based drug information content for PillsCard.com, with a focus on translating clinical guidelines and pharmacological data into practical, accessible guidance for patients, caregivers, and healthcare professionals. He is a member of several professional pharmacy organisations and maintains active continuing education in paediatric pharmacotherapy.
Medical Disclaimer
The information provided in this article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. It should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider — such as your child's paediatrician, allergist, or pharmacist — before starting, stopping, or changing any medication. Individual treatment decisions depend on the specific clinical circumstances, and the recommendations in this article may not apply to every patient. PillsCard.com and the author accept no liability for actions taken based on the content of this article. If your child is experiencing a medical emergency, call your local emergency services immediately.